Posted in | News

Nanogen Begins Shipment of Congestive Heart Failure Product

Nanogen, Inc., developer of advanced diagnostic products, announced today that it has begun shipment of its congestive heart failure (CHF) product, the StatusFirstTM CHF NT-proBNP rapid test. The product is CE-marked and has been cleared by the FDA for diagnostic use with EDTA plasma samples.

The StatusFirst CHF test measures circulating levels of NT-proBNP, a biomarker for heart disease, and provides a quantitative assessment of the biomarker’s concentration in as little as 15 minutes via a small, low cost reader. The test and reader are designed for use in emergency rooms and hospital laboratories.

"With an aging population and more people surviving myocardial infarctions (MI), the market for cardiac diagnostics related to heart failure is expected to exceed $500 million annually in the next five years," said David Ludvigson, Nanogen president and chief operating officer. "This product was developed by Nanogen and complements the rapid cardiac tests for MI we acquired last year. The StatusFirst CHF product is an important addition as we build our point-of-care rapid testing franchise."

NT-proBNP is a derivative of the hormone brain natriuretic peptide, which is released in response to cardiac stress and has been demonstrated in numerous clinical studies to be an accurate and reliable indicator of cardiac disease risk. The StatusFirst CHF product results correlate with central lab methods that use NT-proBNP immunodiagnostic methods. A version of the product that will use whole blood for the sample is currently under development for the U.S. market, which will improve its marketability for use in emergency departments and other critical care settings.

The StatusFirst CHF product has been developed by Nanogen under license from Roche and is being manufactured for Nanogen by Princeton BioMeditech Corporation (PBM). Distribution in the United States will be handled by PBM’s affiliate LifeSign.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanogen. (2019, March 19). Nanogen Begins Shipment of Congestive Heart Failure Product. AZoNano. Retrieved on July 18, 2024 from

  • MLA

    Nanogen. "Nanogen Begins Shipment of Congestive Heart Failure Product". AZoNano. 18 July 2024. <>.

  • Chicago

    Nanogen. "Nanogen Begins Shipment of Congestive Heart Failure Product". AZoNano. (accessed July 18, 2024).

  • Harvard

    Nanogen. 2019. Nanogen Begins Shipment of Congestive Heart Failure Product. AZoNano, viewed 18 July 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.